Scott Cousins is a Retinal Diseases and Treatments physician affiliated with Duke Medical Center. OpenAlex indexes 267 publications with 9,289 citations (h-index 53); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Ophthalmology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Scott Cousins, MD, is affiliated with Duke Medical Center. The public record shows 267 publications with 9,289 citations (h-index 53), centered on Retinal Diseases and Treatments, Retinal Imaging and Analysis, Glaucoma and retinal disorders. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 5 companies, 8 NIH-funded awards (2005–2024).
- Top research focus: Retinal Diseases and Treatments
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 125.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD
Sponsor: Duke University
Industry payments
Updated 27 Aug 2026
5 companies reported payments to CMS in program years 2021–2023. These are public disclosures, not judgments. The latest:
- Notal Vision, Inc.Program year20231 payment
- Alimera Sciences, Inc.Program year20231 payment
- Astellas Pharma US IncProgram year20231 payment
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
100%alpha-Adrenergic Agonist100%Brimonidine Tartrate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
8 NIH research awards on record, funded 2005–2024 per NIH RePORTER. The latest:
- Mitochondrial-Targeted Therapy for Macular Degeneration
Eclipse Life Sciences, Inc.
FY2024$735,619R44EY034732 - Mitochondrial-Targeted Therapy for Macular Degeneration
Eclipse Life Sciences, Inc.
FY2023$749,999R44EY034732 - Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases
Eyedesis Biosciences, Llc
FY2017$225,030R41EY027219
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities
Progress in Retinal and Eye Research
2020 - The Project Baseline Health Study: a step towards a broader mission to map human health
npj Digital Medicine
2020 - Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints
American Journal of Ophthalmology
2018
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/scott-cousins-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/scott-cousins-0461248
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Scott-Cousins-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/DukeEye/posts/congratulations-to-dr-scott-cousins-retina-specialist-at-duke-eye-center-for-bei/152932721412979
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
emedevents.com/speaker-profile/scott-w-cousins
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Abbruzzese, MD
Duke Medical Center
David Durack, MD
Duke Medical Center
Leonard Prosnitz, MD
Duke Medical Center
Brian Czito, MD
Duke Medical Center